[DNA topoisomerase inhibitor].
Copyright policy )[DNA topoisomerase inhibitor].
CPT-11 and Topotecan are a new semisynthetic derivative of CPT, and have been shown to inhibit DNA topoisomerase I and to have a strong antitumor activity with low toxicity against murine tumor. On the other hard, the new antitumor compounds, NC-190 and IST-622 have been shown to inhibit DNA topoisomerase II, and the clinical study are currently under progress. A phase II study of CPT-11 demonstrated that CPT-11 was a very active agent which a acceptable toxicities against patient with advanced non-small cell lung cancer and small cell lung cancer.
- Aichi Cancer Center Japan
Male, Lung Neoplasms, Antineoplastic Agents, Irinotecan, Drug Administration Schedule, Mice, Carcinoma, Non-Small-Cell Lung, Animals, Humans, Phenazines, Camptothecin, Female, Carcinoma, Small Cell, Topoisomerase I Inhibitors, Topotecan
Male, Lung Neoplasms, Antineoplastic Agents, Irinotecan, Drug Administration Schedule, Mice, Carcinoma, Non-Small-Cell Lung, Animals, Humans, Phenazines, Camptothecin, Female, Carcinoma, Small Cell, Topoisomerase I Inhibitors, Topotecan
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!